Corporate Presentation
January 5, 2023
Forward-Looking Statements
This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the potential benefits of Vaxcyte's vaccine candidates, including breadth of coverage and the ability to deliver a potentially best-in-class pneumococcal conjugate vaccine; demand for Vaxcyte's vaccine candidates; the timing of the initiation, progress and expected results of Vaxcyte's preclinical studies, clinical trials and research and development plans (including, the availability of data for the VAX-24 Phase 2 and Phase 3 studies and
related regulatory interactions; the submission of a VAX-24 infant IND application and initiation of such study; the design of the VAX-31 (formerly called VAX-XP) clinical program, the submission of such IND and the availability of topline data; the announcement of guidance for VAX-A1; the achievement of future funding milestones; the use and availability of funds from CARB-X; the growth and expansion of the pneumococcal vaccine market, and the potential for Vaxcyte's PCV franchise to have sustained leadership within such market; the potential conversion by the pneumococcal vaccine market to a prime-boost schedule; the market opportunity for Vaxcyte's vaccines; Vaxcyte's expectations regarding the potential benefits, spectrum coverage, regulatory pathway, adoption speed and immunogenicity of its vaccine candidates; VAX-31's advancement as a follow-on candidate to VAX-24; and other statements that are not historical fact. The
words "anticipate," "believe," "continue," "could," "designed," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target,"
"will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
These forward-looking statements are based on Vaxcyte's current expectations and actual results and timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, including, without limitation, risks related to Vaxcyte's product development programs, including development timelines, success and timing of chemistry, manufacturing and controls and related manufacturing activities; potential delays or inability to obtain and maintain required regulatory approvals for its vaccine candidates; the risks and uncertainties inherent with preclinical and clinical development processes; the success, cost and timing of all development activities and clinical trials; sufficiency of cash and other funding to support Vaxcyte's development programs and other operating expenses; and the ongoing COVID-19 pandemic, which could materially and adversely affect Vaxcyte's business and operations. These and other risks are described more fully in Vaxcyte's filings with the Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q filed with the SEC on November 7, 2022 or in other documents Vaxcyte subsequently files with or furnishes to the SEC. Vaxcyte undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.
January 5, 2023
2
VAXCYTE MISSION STATEMENT
We are on a global mission to engineer high- fidelity vaccines that protect humankind from the consequences of bacterial diseases.
January 5, 2023
3
Key Corporate Highlights
Clinical-Stage Vaccine Innovation Company - Led by Pneumococcal Conjugate Vaccine (PCV) Franchise
POTENTIAL BEST-IN-CLASS PCV FRANCHISE: VAX-24 & VAX-31
- Scalable platform enabling broader- spectrum carrier-sparingPCVs
- Lead candidate: VAX-24
- Reported positive topline Phase 1/2 data results in adults
- Potential best-in-class24-valent PCV designed to replace SOC in adults and children
- Breakthough Therapy and Fast Track designations in adults
- Follow-oncandidate: VAX-31 (formerly VAX-XP)
CELL-FREE PROTEIN | HIGHLY ATTRACTIVE | ||
SYNTHESIS PLATFORM | PCV MARKET | ||
• | Leverages site-specific | • | Well-defined >$7B market |
conjugation to expose on- | segment poised for | ||
target T- and B-cell antigens | substantial growth | ||
• | Enables carrier-sparing | • | Honors well-understood |
conjugates | PCV MOA | ||
• | Permits production of | • | Leverages established |
"tough-to-make" antigens | surrogate immune | ||
endpoints and clinical | |||
pathways |
• Spectrum of coverage is primary adoption driver
ROBUST DEVELOPMENT | ALIGNED CRITICAL | |
PIPELINE | RESOURCES | |
• Platform unlocks large | • | Strategic alignment with |
market opportunities: | Lonza (manufacturing) | |
- VAX-A1: Novel Group A | • | Seasoned management |
Strep conjugate vaccine | team, directors and advisors | |
- VAX-PG: Novel | • ~1.0B in cash, cash | |
periodontitis therapeutic | equivalents and investments | |
vaccine | as of 9/30/22 pro forma for | |
Oct. 2022 follow-on | ||
offering(1) |
- 31-valentPCV designed to provide coverage for ~95% of PD circulating in the U.S. adult population
- Reflects cash, cash equivalents at September 30, 2022 of $366.2M and net proceeds from October follow-on offering of ~$650.7M.
SOC = Standard-of-Care.
PD = Pneumococcal Disease.
January 5, 2023
4
Experienced Team with Track Record in Vaccines and Biopharma
Management Team
Grant Pickering, MBA | Andrew Guggenhime, MBA | Jim Wassil, MS, MBA | Mark Wiggins, MBA | |||||||||||
CEO & Co-founder | President & CFO | EVP & COO | CBO | |||||||||||
Jakub Simon, MD, MS | Jeff Fairman, PhD | Paul Sauer, MBA | Harp Dhaliwal, MBA | ||||||||||||
CMO | VP Research & Co-founder | SVP PD & Manufacturing | SVP Commercial Mfg & Supply Chain | ||||||||||||
January 5, 2023
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Vaxcyte Inc. published this content on 05 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 January 2023 13:47:05 UTC.